Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

S. A. Bendien; M. M. van Leeuwen; H. S. Lau; A. Ten Brinke; L. E. Visser; E. M. de Koning; G. J. Braunstahl

doi:10.1016/j.rmed.2022.106776

Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

S. A. Bendien^*, M. M. van Leeuwen, H. S. Lau, A. Ten Brinke, L. E. Visser, E. M. de Koning, G. J. Braunstahl

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.

Original language	English
Article number	106776
Pages (from-to)	106776
Journal	Respiratory Medicine
Volume	194
DOIs	https://doi.org/10.1016/j.rmed.2022.106776 https://doi.org/10.1016/j.rmed.2022.106776
Publication status	Published - Apr 2022

Bibliographical note

Access to Document

Cite this

@article{a28d64d4722c439f9299d1f9b0f842e8,

title = "Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation",

abstract = "The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.",

author = "Bendien, {S. A.} and {van Leeuwen}, {M. M.} and Lau, {H. S.} and {Ten Brinke}, A. and Visser, {L. E.} and {de Koning}, {E. M.} and Braunstahl, {G. J.}",

year = "2022",

month = apr,

doi = "10.1016/j.rmed.2022.106776",

language = "English",

volume = "194",

pages = "106776",

journal = "Respiratory Medicine",

issn = "0954-6111",

}

TY - JOUR

T1 - Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

AU - Bendien, S. A.

AU - van Leeuwen, M. M.

AU - Lau, H. S.

AU - Ten Brinke, A.

AU - Visser, L. E.

AU - de Koning, E. M.

AU - Braunstahl, G. J.

PY - 2022/4

Y1 - 2022/4

N2 - The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.

AB - The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.

UR - http://www.scopus.com/inward/record.url?scp=85125445464&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2022.106776

DO - 10.1016/j.rmed.2022.106776

M3 - Article

C2 - 35221150

AN - SCOPUS:85125445464

SN - 0954-6111

VL - 194

SP - 106776

JO - Respiratory Medicine

JF - Respiratory Medicine

M1 - 106776

ER -

Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this